Detalles de la búsqueda
1.
Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia.
Haematologica
; 109(6): 1973-1976, 2024 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38385304
2.
Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy.
Clin Transl Sci
; 16(12): 2483-2493, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37920921
3.
Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.
Trials
; 24(1): 591, 2023 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37715270
4.
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML.
Trials
; 22(1): 765, 2021 Nov 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34732236
Resultados
1 -
4
de 4
1
Próxima >
>>